Skip to main content
Wed, Apr 8, 2026
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
Sample data
HealthUnited States1 sourcesNeutral

Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial

MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease. The GARDian3 trial enrolled ...

TA
timothy alexander
via Mychesco
ShareRead original

Read the full article at Mychesco →

Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Mychesco
Mychesco
NewsDataUS

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
Physician Board Exam Results March 2026 to be Released Today (April 8, 2026)
Next
Iran Ceasefire: Controlled Conflict, Inevitable Talks

Related Articles

Plus Therapeutics Gains After FDA Grants Orphan Drug Status To REYOBIQHealth
Plus Therapeutics Gains After FDA Grants Orphan Drug Status To REYOBIQ
Unknown-9h ago-2 sources
DAX Soars Nearly 5% As Stocks Rally On U.S.-Iran Ceasefire NewsHealth
DAX Soars Nearly 5% As Stocks Rally On U.S.-Iran Ceasefire News
Unknown-11h ago-2 sources
Elektroimportoren AS Full Year Income FallsHealth
Elektroimportoren AS Full Year Income Falls
Unknown-11h ago-1 sources